Choosing initial antihypertensive drug therapy for the uncomplicated hypertensive patient

Journal of Clinical Hypertension

Volumn 3, Issue 1, 2001, Pages 37-44

  Moore, Michael A ^a,b  

^a WAKE FOREST SCHOOL OF MEDICINE   (United States)

^b NONE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACEBUTOLOL; AMLODIPINE; ANGIOTENSIN 2 RECEPTOR ANTAGONIST; ANTIHYPERTENSIVE AGENT; ATENOLOL; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CARVEDILOL; CHLORTALIDONE; CHOLESTEROL; CLONIDINE; DILTIAZEM; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DOXAZOSIN; ELECTROLYTE; ENALAPRIL; GUANABENZ; HYDRALAZINE; HYDRALAZINE PLUS HYDROCHLOROTHIAZIDE PLUS RESERPINE; HYDROCHLOROTHIAZIDE; LABETALOL; LOOP DIURETIC AGENT; LOSARTAN; METHYLDOPA; METOPROLOL; MINOXIDIL; PRAZOSIN; TERAZOSIN; THIAZIDE DIURETIC AGENT; VALSARTAN; VERAPAMIL;

ADRENERGIC ACTIVITY; ANTIHYPERTENSIVE ACTIVITY; ARTICLE; BLOOD PRESSURE REGULATION; CHOLESTEROL BLOOD LEVEL; CONGESTIVE HEART FAILURE; CONTROLLED STUDY; CORONARY ARTERY DISEASE; DIURETIC THERAPY; DRUG CHOICE; DRUG COST; DRUG EFFICACY; ELECTROLYTE DISTURBANCE; FATIGUE; HEART PALPITATION; HIGH RISK PATIENT; HUMAN; HYPERTENSION; HYPERTRICHOSIS; LASSITUDE; LONG TERM CARE; SEDATION; VASODILATATION; XEROSTOMIA;

EID: 0034950285     PISSN: 15246175     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1524-6175.2001.990830.x     Document Type: Article

References (61)

1. The Sixth Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure
2. Prevention of stroke by antihypertensive drug treatment in older persons with isolated systolic hypertension
3. Swedish trial in old patients with hypertension (STOP-Hypertension) analysis performed up to 1992
4. Health outcomes associated with antihypertensive therapies used as first line therapies
5. Chinese trial on isolated systolic hypertension
6. Current strategies for management of hypertensive renal disease
7. Effects of intensive blood-pressure lowering and low-dose aspirin in patients with hypertension: Principal results of the Hypertension Optimal Treatment (HOT) randomized trial
8. Hypertension-related morbidity and mortality in the southeastern United States
9. The role of hypertension in the pathogenesis of heart failure: A clinical mechanistic overview
10. The impact of the new HEDIS guidelines: Practical considerations
11. Long-term effects on sexual function of five antihypertensive drugs and nutritional hygienic treatment of hypertensive men and women
12. Effects of treatment on morbidity in hypertension: Results in patients with diastolic blood pressure averaging 115 through 129 mm Hg
13. Effects of treatment on morbidity in hypertension: Results in patients with diastolic blood pressure averaging 90 through 114 mm Hg
14. Five year findings of the Hypertension Detection and Follow-up Program. I: Reduction in mortality of persons with high blood pressure, including mild hypertension
15. Treatment of mild hypertension: A five year controlled trial
16. Multiple risk factor intervention trial. Risk factor changes and mortality results
17. Treatment of hypertension: Drug therapy
18. Minoxidil, nadalol, and a diuretic. Once a day therapy for resistant hypertension
19. National recommendations for the pharmacologic treatment of hypertension. Should they be revised?
20. Major cardiovascular events in hypertensive patients randomized to doxazosin vs. chlorthalidone
21. The effect of carvedilol on morbidity and mortality in patients with chronic heart failure
22. Treatment of hypertension: Drug therapy
23. Short and long term (six year) hemodynamic effects of labetalol in essential hypertension
24. Rationale and design for the Antihypertensive and Lipid Lowering Treatment to Prevent Heart Attack Trial (ALLHAT)
25. Tolerability, safety, and quality of life and hypertensive therapy. The case for low-dose diuretics
26. Evidence for the efficacy of low-dose diuretic monotherapy
27. Diuretics and cardiovascular risk factors
28. Diuretic complications
29. Hypokalemia associated with diuretic used and cardiovascular events in the systolic hypertension in the elderly program
30. Beta-blockers versus diuretics in hypertensive men: Main results from the HAPPY Trial
31. Adverse reactions to bendrofluazide and propranalol for the treatment of mild hypertension
32. Randomized trial of old and new antihypertensive drugs in elderly patients: Cardiovascular mortality and morbidity in the Swedish Trial in Old Patients with Hypertension-2 study
33. Beta adrenergic blockade for survivors of acute myocardial infarction
34. Are beta blockers efficacious as first-line therapy for hypertension in the elderly?
35. Primary prevention with metroprolol in patients with hypertension. Mortality from the MAPHY study
36. Metropolol versus thiazide diuretics in hypertension. Morbidity results from the MAPHY study
37. Restoring function in failing hearts: The effects of beta blockers
38. Anti-renin system therapy. A new horizon for understanding and treating hypertension
39. Treatment of hypertension: Drug therapy
40. Choice of initial antihypertensive medication may influence the extent to which patients stay on therapy: A community-based study of a losartan-based regiment vs. usual care
41. Effects of bradykinin-receptor blockade on the response to angiotensin-converting enzyme inhibitor in normotensive and hypertensive subjects
42. Chymase-dependent angiotensin II forming systems in humans
43. Determinants of angiotensin II generation during converting enzyme inhibition
44. Antihypertensive therapy with MK 421: Angiotensin II-renin relationships to evaluate efficacy of converting enzyme blockade
45. Evidence that TGF-B should be a therapeutic target in diabetic nephropathy
46. Effect of ACE inhibition on endothelial dysfunction in patients with chronic heart failure
47. Pathophysiology of the syndrome of hyporeninemic hypoaldosteronism
48. Treatment of hypertension: Drug therapy
49. Renin and angiotensin
50. Focus on losartan
51. Losartan and low-dose hydrochlorothiazide in patients with essential hypertension
52. Irbesartan in combination with hydrochlorothiazide in mild-to-moderate hypertension
53. Characteristics of 9194 patients with left ventricular hypertrophy. The LIFE study
54. Clinical implications of the trough: Peak ratio
55. Efficacy of angiotensin II antagonists: A comparative analysis
56. Effects of losartan on a background of hydrochlorothiazide in patients with hypertension
57. Reduced diuretic-induced hypokalemia with valsartan in combination with HCTZ
58. Drugs used for the treatment of myocardial ischemia
59. Randomized double-blind comparison of placebo and active treatment for older patients with isolated systolic hypertension
60. Nefedipine: Dose-related increase in mortality in patients with coronary heart disease
61. Comparison of amlodipine and benazepril monotherapy to amlodipine plus benazepril in patients with systemic hypertension: A randomized, double-blind, placebo-controlled, parallel-group study